This year’s Top 10 U.S. Biopharma Clusters List features the same 10 regions as last year’s GEN List, but the top seven occupy slightly different positions than they did in the 2014 list.
One factor in the changes this past year has been a recovering venture capital market, which pushed numbers above last year’s totals for most, though not all regions (three showed declines and one was flat over 2013). For example, the top region racked up $1.82 billion in 2014, versus $1.447 billion in 2013. Click here to read more.
